<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet title="XSL_formatting" type="text/xsl" href="http://webarchive.nationalarchives.gov.uk/20100528142817/http://www.nice.org.uk/rss/nolsol.xslt"?>

 









<rss version="2.0">
	<channel>
		<title>NICE | Nice Front Page (Welcome to NICE)</title>
		<link>http://webarchive.nationalarchives.gov.uk/20100528142817/http://www.nice.org.uk/</link>
		<description>NICE is an independent organisation responsible for providing national guidance on promoting good health and preventing and treating ill health.</description>
		<language>en-gb</language>
		<copyright>Copyright (c) 2007 National Institute for Health and Clinical Excellence</copyright>
		<image>
			<title>NICE</title>
			<url>http://webarchive.nationalarchives.gov.uk/20100528142817/http://www.nice.org.uk/images/rss-logo.gif</url>
			<link>http://webarchive.nationalarchives.gov.uk/20100528142817/http://www.nice.org.uk/</link>
		</image>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/2010089EverolimusForRenalCellCarcinoma.jsp]]></guid>
			<title><![CDATA[NICE unable to recommend everolimus for advanced renal cell carcinoma]]></title>
			<description><![CDATA[n its latest draft guidance, NICE has been unable to recommend everolimus (Afinitor, Novartis) for the second line treatment of advanced renal cell carcinoma because it does not provide enough benefit to patients to justify its high cost.]]></description>
			<pubdate>2 Jul 2010, 09:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/2010089EverolimusForRenalCellCarcinoma.jsp]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/news/NICELaunchesQualityStandards.jsp]]></guid>
			<title><![CDATA[NICE launches quality standards for the NHS]]></title>
			<description><![CDATA[]]></description>
			<pubdate>1 Jul 2010, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/news/NICELaunchesQualityStandards.jsp]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/news/NHSEvidenceCallsForGuidanceProducers.jsp]]></guid>
			<title><![CDATA[NHS Evidence calls for guidance producers]]></title>
			<description><![CDATA[]]></description>
			<pubdate>29 Jun 2010, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/news/NHSEvidenceCallsForGuidanceProducers.jsp]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/alcoholdependenceandharmfuldrinking.jsp]]></guid>
			<title><![CDATA[How to manage alcohol dependence and harmful drinking: NICE opens public consultation on draft guideline]]></title>
			<description><![CDATA[In draft guidance out today (24 June), NICE is calling for improvements to be made across the NHS in the diagnosis, assessment and management of people who are alcohol dependent or drinking harmful amounts of alcohol.]]></description>
			<pubdate>24 Jun 2010, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/alcoholdependenceandharmfuldrinking.jsp]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/COPDUpdate.jsp]]></guid>
			<title><![CDATA[NICE updates chronic obstructive pulmonary disease guideline to improve patient care]]></title>
			<description><![CDATA[Diagnosis and management of adults with chronic obstructive pulmonary disease (COPD) in primary and secondary care can be better, according to new final guidance published today (23 June).]]></description>
			<pubdate>23 Jun 2010, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/COPDUpdate.jsp]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/NICERecommendsPemetrexedForTheMaintenanceTreatmentOfNonSmallCellLungCancer.jsp]]></guid>
			<title><![CDATA[NICE recommends pemetrexed for the maintenance treatment of non-small-cell lung cancer]]></title>
			<description><![CDATA[NICE has today issued final guidance to the NHS recommending pemetrexed (Alimta, Eli Lilly) for the maintenance treatment of non-small-cell lung cancer.]]></description>
			<pubdate>23 Jun 2010, 09:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/NICERecommendsPemetrexedForTheMaintenanceTreatmentOfNonSmallCellLungCancer.jsp]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/PressReleaseCVDPrevention.jsp]]></guid>
			<title><![CDATA[Cut salt and saturated fat levels in processed food to save thousands of lives, says NICE]]></title>
			<description><![CDATA[Tens of thousands of lives could be saved, and millions of people spared the suffering of living with the effects of heart disease and stroke, simply by producing healthier food says new NICE guidance today (Tuesday 22 June). &nbsp;The guidance calls for the food industry to further reduce the salt and saturated fats in the food it produces, building on the good work already started.]]></description>
			<pubdate>22 Jun 2010, 00:01:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/PressReleaseCVDPrevention.jsp]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/ErlotinibForNonSmallCellLungCancer.jsp]]></guid>
			<title><![CDATA[NICE unable to recommend erlotinib for the maintenance treatment of non-small-cell lung cancer]]></title>
			<description><![CDATA[In preliminary guidance issued today, NICE has been unable to recommend erlotinib (Tarceva, Roche Products) as a maintenance treatment for people with non small cell lung cancer who have had first line treatment and their disease had remained stable.]]></description>
			<pubdate>16 Jun 2010, 17:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/ErlotinibForNonSmallCellLungCancer.jsp]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/2010071sexeducationpressrelease.jsp]]></guid>
			<title><![CDATA[Sex, relationships and alcohol education in schools and colleges can be improved, says NICE]]></title>
			<description><![CDATA[All children and young people are entitled to high-quality education about sex, relationships and alcohol to help them make responsible decisions and acquire the skills and confidence to delay sex until they are ready.]]></description>
			<pubdate>17 Jun 2010, 00:01:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/2010071sexeducationpressrelease.jsp]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/NICEReviewsWaysToReduceDrinkDrivingInjuries.jsp]]></guid>
			<title><![CDATA[Cutting drink-drive limit 'could save 168 lives in the first year']]></title>
			<description><![CDATA[Around 16,000 road-traffic injuries and 170 deaths could be prevented in the first year if the government lowers the blood alcohol limit for drivers, says a new study of the drink-drive laws.]]></description>
			<pubdate>16 Jun 2010, 10:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/NICEReviewsWaysToReduceDrinkDrivingInjuries.jsp]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/NICEFinalDraftGuidanceRecommendsImprovedAccessToPsoriaticArthritisTreatments.jsp]]></guid>
			<title><![CDATA[NICE final draft guidance recommends improved access to psoriatic arthritis treatments]]></title>
			<description><![CDATA[]]></description>
			<pubdate>15 Jun 2010, 15:40:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/NICEFinalDraftGuidanceRecommendsImprovedAccessToPsoriaticArthritisTreatments.jsp]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/NICEAppraisalOfEltrombopag.jsp]]></guid>
			<title><![CDATA[NICE appraisal of eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura]]></title>
			<description><![CDATA[In preliminary guidance published today (10 June 2010), eltrombopag (Revolade, GlaxoSmithKline) is not recommended for treating chronic immune (idiopathic) thrombocytopenic purpura (ITP) in splenectomised adults who do not respond to other treatments (for example, corticosteroids, immunoglobulins), or as second-line treatment for non-splenectomised adults when surgery is not advised.]]></description>
			<pubdate>10 Jun 2010, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/NICEAppraisalOfEltrombopag.jsp]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/limitedbenefithighcostresponsiblefornicesdecisiononlapatinib.jsp]]></guid>
			<title><![CDATA[Limited benefit and high cost responsible for NICE's decision on lapatinib]]></title>
			<description><![CDATA[Following extensive consultation with pharmaceutical companies, healthcare professionals, charities and patient groups, the National Institute for Health and Clinical Excellence has issued draft guidance recommending lapatinib, in combination with capecitabine, for women with advanced or metastatic HER2-positive breast cancer but only in the context of clinical trials.]]></description>
			<pubdate>10 Jun 2010, 00:01:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/limitedbenefithighcostresponsiblefornicesdecisiononlapatinib.jsp]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/SedationInChildren.jsp]]></guid>
			<title><![CDATA[NICE to help NHS improve standards on child sedation]]></title>
			<description><![CDATA[New advice is being developed to improve NHS standards on sedating anxious young patients. There is currently no national guidance, which means those aged 19 and under who need sedation before a therapeutic or diagnostic procedure might be given drugs that may be ineffective or unsafe.]]></description>
			<pubdate>17 May 2010, 09:30:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/SedationInChildren.jsp]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/features/NICEtoProduceGuidanceToTackleSmoking.jsp]]></guid>
			<title><![CDATA[NICE to produce guidance to tackle smoking]]></title>
			<description><![CDATA[NICE is to produce a range of public health guidance to encourage people to give up smoking, after the Department of Health announced the latest topics to be referred to our work programme.]]></description>
			<pubdate>16 Mar 2010, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/features/NICEtoProduceGuidanceToTackleSmoking.jsp]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/features/NICEIssuesGuidanceToPromoteSafetyStandardsForDonorBreastMilk.jsp]]></guid>
			<title><![CDATA[NICE issues guidance to promote safety standards for donor breast milk]]></title>
			<description><![CDATA[NICE has published a clinical guideline on donor milk banks to provide recommendations on the safe and effective operation of such services, and will help to ensure that good practice is consistent across the UK.]]></description>
			<pubdate>24 Feb 2010, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/features/NICEIssuesGuidanceToPromoteSafetyStandardsForDonorBreastMilk.jsp]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/features/LookedAfterGuidanceToImproveQualityofLife.jsp]]></guid>
			<title><![CDATA[Looked-after guidance to improve quality of life for children and young people]]></title>
			<description><![CDATA[NICE and SCIE (the Social Care Institute for Excellence) have now issued joint draft guidance to improve the quality of life for looked-after children and young people.]]></description>
			<pubdate>16 Feb 2010, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/features/LookedAfterGuidanceToImproveQualityofLife.jsp]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/press_releases.jsp?domedia=1&mid=270F36EE-19B9-E0B5-D4ACAB95EAF9B93C]]></guid>
			<title><![CDATA[NICE to publish final guidance on topotecan for the treatment of small-cell lung cancer and preliminary recommendations for bevacizumab for metastatic colorectal cancer]]></title>
			<description><![CDATA[Final guidance published on 25 November recommends topotecan as a second line treatment for relapsed lung cancer, and preliminary recommendations published for consultation on 24 November state that bevacizumab for the treatment of metastatic colorectal cancer does not represent a cost-effective use of NHS resources.]]></description>
			<pubdate>24 Nov 2009, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/pressreleases/press_releases.jsp?domedia=1&mid=270F36EE-19B9-E0B5-D4ACAB95EAF9B93C]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/news/newsarchive/2009/howniceguidanceishelpingthenhsthroughfinancialuncertainty.jsp]]></guid>
			<title><![CDATA[How NICE guidance is helping the NHS through financial uncertainty]]></title>
			<description><![CDATA[With the current financial situation in the UK set to result in challenging times for the NHS, the role of NICE will become ever more important. As NHS service providers look to balance budgets, NICE guidance will continue to play its part through ensuring quality care for patients whilst making sure service providers are aware of how they can best spend their limited resources.]]></description>
			<pubdate>15 Nov 2009, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/news/newsarchive/2009/howniceguidanceishelpingthenhsthroughfinancialuncertainty.jsp]]></link>
			
			
			
		</item>
		<item>
			<guid><![CDATA[http://www.nice.org.uk/newsroom/features/CitizensCouncilReport.jsp]]></guid>
			<title><![CDATA[Feature: Departing from the threshold]]></title>
			<description><![CDATA[Are there circumstances where NICE should recommend treatments we would not normally consider cost effective? Our Citizens Council considered the issue, and presented its report at the NICE Board meeting on 22 May.]]></description>
			<pubdate>3 Jun 2009, 00:00:00</pubdate>
			<link><![CDATA[http://www.nice.org.uk/newsroom/features/CitizensCouncilReport.jsp]]></link>
			
			
			
		</item>
		
	</channel>
</rss>
